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Abstract: Coelibactin is a putative non-ribosomally synthesized peptide with predicted 
zincophore activity and which has been implicated in antibiotic regulation in Streptomyces 
coelicolor A3(2). The coelibactin biosynthetic pathway contains a stereo- and regio-specific 
monooxygenation step catalyzed by a cytochrome P450 enzyme (CYP105N1). We have 
determined the X-ray crystal structure of CYP105N1 at 2.9 Å and analyzed it in the context 
of the bacterial CYP105 family as a whole. The crystal structure reveals a channel between 
the α-helical domain and the β-sheet domain exposing the heme pocket and the long helix I 
to the solvent. This wide-open conformation of CYP105N1 may be related to the bulky 
substrate coelibactin. The ligand-free CYP105N1 structure has enough room in the 
substrate access channel to allow the coelibactin to enter into the active site. Analysis of 
typical siderophore ligands suggests that CYP105N1 may produce derivatives of 
coelibactin, which would then be able to chelate the zinc divalent cation.  








Cytochrome P450 monooxygenases (CYP or P450) constitute a superfamily of heme-containing 
enzymes with more than 16,000 known genes distributed among all biological kingdoms [1]. CYP 
proteins have diverse primary amino acid sequences and are grouped into different families when they 
have less than 40% amino acid sequence identity and into sub-families of the same family when they 
have more than 55% amino acid sequence identity [2]. CYP enzymes are involved both in endogenous 
biosynthetic pathways e.g., sterol, steroid, vitamin and hormone biosynthesis and in the metabolism of 
xenobiotic compounds [3]. Enzymatically, CYP catalyzes the molecular scission of atmospheric 
dioxygen, generally introducing one oxygen atom into a non-activated carbon-hydrogen bond of the 
substrate with an exceptionally high degree of regio- and stereo-selectivity, the second oxygen atom 
reduced to a water molecule [4,5]. Basic CYP enzymatic reactions include C-hydroxylation, 
heteroatom oxygenation, heteroatom release (dealkylation), epoxide formation and group migration. 
Recently, more complex enzymatic reactions including chlorine oxygenation, dimer formation, ring 
coupling, ring formation, ring contraction and aromatic dehalogenation have also been attributed as 
being CYP-catalyzed [6]. Nearly all CYPs use NAD(P)H as a source of electrons for the activation of 
dioxygen and a redox partner(s) which delivers the electrons to the iron atom of the CYP prothetic 
heme (generally NAD(P)H cytcohrome P450 reductase for eukaryotic CYPs and combination of a 
ferredoxin and a ferredoxin reductase for prokaryotic CYPs) [7].  
Although most bacteria have no CYPs encoded within their genomes, the actinomycetes have 
provided a rich source of CYP sequences [8]. The genus Streptomyces are distinguished by their ability 
to produce a wide array of biologically active secondary metabolites, many of which have been applied 
as antibiotics in medicine [9,10]. Additionally, many of these secondary metabolite biosynthetic 
pathways have one or more cytochrome P450 catalyzed steps which are essential in producing the final 
pharmacologically active molecule [11]. By far the most prevalent CYP families in Streptomyces are 
the CYP105 and the CYP107 families, with members present in each completely sequenced 
streptomycete genome as well as being found in numerous other Streptomyces species [1]. Generally, 
CYP107s seem to have been recruited into antibiotic biosynthetic pathways where they play roles in 
oxidative tailoring the final antibiotic molecule. For example, CYP107A1 (EryF), from the 
actinomycete bacterium Saccharopolyspora erythraea, is responsible for the final step of the 
biosynthesis of the antibiotic erythromycin [12] and CYP107L1 (PikC) from Streptomyces venezulae 
is responsible for the final step in producing the active antibiotic picromycin [13]. In contrast, CYP105 
enzymes are seemingly more promiscuous in their range of catalytic activities with some members 
having a diverse range of substrates such as CYP105D1, which has been shown to be a xenobiotic 
metabolising P450 [14], while other members such as CYP105P1 have strict substrate specificity 
where it is involved in the biosynthesis of the polyene antifungal agent filipin [15]. 
Streptomyces coelicolor A3(2) has been investigated extensively as a model system for the study of 
morphological and physiological development of Streptomyces and for investigation of the genetic 
control of secondary metabolites [8]. S. coelicolor was the first streptomycete to have its genome 
sequenced and consists of a 8,667,507 bp linear chromosome containing approximately 7825 genes 
including 20 gene clusters which direct the biosynthesis of known or predicted secondary metabolites [9]. 
Of the 18 CYP gene sequences in S. coelicolor, 3 CYPs were directly linked to these secondary 
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metabolite gene clusters [9,16]. First, CYP158A2 (SCO1206) as determined by our laboratory, is 
involved in the oxidative C–C coupling of flaviolin producing diflaviolin, which was then polymerized 
to melanin-like pigments that are thought to afford protection to the soil dwelling bacterium from the 
deleterious effects of UV irradiation [17]. Second, CYP170A1 (SCO5223), which we determined as 
catalyzing two sequential oxidation reactions of the terpenoid epi-isozizaene, through two epimers  
of albaflavenol, to the single sequiterpene antibiotic, albaflavenone [18]. Both the crystal structures  
of CYP158A2 and CYP170A1 were resolved allowing for detailed mechanistic insight into  
the catalytic activities [17,19]. 
Figure 1. (A) The secondary metabolite gene cluster which encodes for the biosynthesis of 
coelibactin in Streptomyces coelicolor A3(2). Genes SCO7676-80 encode a ferredoxin 
(SCO7676, colored black) and four putative metal transport proteins (SCO7677-80). Genes 
SCO7681-92 encode the coelibactin biosynthetic pathway including the non-ribosomal 
peptide synthase genes (SCO7682, 7683, colored grey) which synthesise the initial 
coelbactin molecule which is then enzymatically tailored by CYP105N1 (SCO7686, colored 
black) and possibly by proteins of unknown function (SC7684, 7685, 7688 and 7692). 
SCO7689 and SCO7690 encode putative ABC transporters. (B) The predicted structure of 
coelibactin as determined by analysis of the sequence of the nonribosomal peptide 
synthetase (NRPS) proteins and prior to enzymatic tailoring. 
 
The final S. coelicolor A3(2) CYP unequivocally linked to the biosynthesis of a predicted 
secondary metabolite in S. coelicolor A3(2) is CYP105N1 (SCO7686). CYP105N1 is one of 17 genes 
from the gene cluster assigned as being responsible for the production of coelibactin (Figure 1A). 
Coelibactin is a non-ribosomal peptide derivative whose chemical structure was predicted by 
computational analyses and from the sequence of its non-ribosomal peptide synthetase (SCO7682, 
7683; Figure 1B) [9]. However, coelibactin itself, or any intermediate, has not been identified in  
S. coelicolor A3(2) extracts and hence its chemical structure awaits elucidation. Physiologically, 
coelibactin has predicted zincophore activity and the expression of the coelibactin gene cluster has 
been shown to abolish antibiotic production in S. coelicolor A3(2) indicating that coelibactin is an 
important regulator of antibiotic biosynthesis [20,21]. Herein, we present the ligand-free X-ray  
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crystal structure of CYP105N1, which is predicted to be involved in production of the final and 
biologically active coelibactin molecule. Further, a biochemical reaction mechanism is proposed for  
CYP105N1, which if accurate, will afford the necessary chemical properties to the coelibactin 
molecule in order to chelate zinc.  
2. Results and Discussion 
2.1. The Role of the Coelibactin Operon in Zinc Chelation and Bioinformatics Analysis 
Recently, two reports have emerged in the literature which have implicated the coelibactin gene 
cluster in indirectly regulating antibiotic production via its role as a zincophore [20,21]. Zinc is a 
common element in soil and the second most abundant transition metal in cells after iron. Many 
proteins utilize Zn structurally and if it is allowed to accumulate intracellularly, it is toxic. Previously, 
intracellular Zn levels were thought to be regulated in bacteria by transport proteins. However, two 
regulatory mutants of S. coelicolor A3(2) (zur and absC) were characterized and experimental 
evidence suggests they work by inhibiting expression of the coelibactin gene cluster. In a complicated 
scenario, the intracellular concentration of zinc directly affects the function of both of these repressor 
proteins on the expression of the coelibactin gene cluster, suggesting that coelibactin putatively 
functions by controlling the intracellular concentrations of zinc in S. coelicolor A3(2). In the absence 
of Zur and AbsC, the coelibactin pathway is switched on and antibiotic biosynthesis is lost. 
Conversely, in the presence of Zur and AbsC, the coelibactin pathway is switched off and antibiotic 
production can occur. Bioinformatic analysis of both the NRPS (nonribosomal peptide synthetase) 
proteins reveals that putative homologues of this pathway exist in other streptomycetes. However 
production of other “coelibactin-like” molecules in other organisms does not require a CYP105N1 
homologue in the biosynthetic pathway. For example, in Salinispora tropica, a gene encoding a 
CYP105N1 homologue is missing in its putative zincophore biosynthetic pathway, but two other P450 
enzymes are present—CYP1000A1 (Strop_2825) and CYP1000B1 (Strop_2829)—Which constitute 
two new P450 families with no homology to any existing P450 member. Clearly, the final 
‘coelibactin’-structural moiety is different dependent upon the actinomycete in question with the 
differences possibly at the level of the tailoring of the final molecule. In an effort to elucidate both the 
final coelibactin molecule and the putative CYP105N1 substrate, we undertook a metabolomic 
approach by examining both the Zur mutant in which the coelibactin gene cluster was overexpressed 
and by incubating metabolite extracts with CYP105N1 to trap a potential substrate. No promising 
candidates were observed in extract analysis. Other laboratories have also tried to identify the product 
of the coelibactin biosynthetic cluster but with no success (M. Bibb, personal communication). 
2.2. Bioinformatic Analysis of CYP105N1 
The CYP105 family of the P450 superfamily of enzymes is one of the most widespread and studied 
P450 families amongst bacteria and to-date all sequenced streptomycete genomes have at least one 
member [1]. Many other CYP105s in streptomycetes were identified through antibiotic gene cluster 
analysis, through their identification as being involved in key industrial biotransformations e.g., 
CYP105A3 from Streptomyces carbophilus involved in the conversion of ML-236B to pravastatin, a 
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major cholesterol lowering drug through inhibition of HMG-CoA reductase [22], and those involved in 
drug metabolite production for toxicology testing e.g., CYP105D1 from Streptomyces griseus which 
has a diverse substrate range in the xenobiotics which it can metabolize [14]. Consequently, the 
chemical substrate range for CYP105 members is widespread and diverse. Given their obvious 
importance much interest has focused on the structure/function of CYP105 P450s. Hence, the crystal 
structure of 5 CYP105 members with diverse catalytic activities have been solved: CYP105A1 
involved in vitamin D3 metabolism [23]; CYP105A3, involved in the biosynthesis of pravastatin [24]; 
moxA (CYP105AB3), involved in xenobiotic degradation [25]; and CYP105P1 and CYP105D6 
involved in the production of the antifungal agent filipin [15]. CYP105N1, was recently identified in  
S. coelicolor A3(2) as belonging to a gene cluster described herein.  
2.3. CYP105N1 Expression, Purification and Spectral Analysis 
Similarly to the previous expression of some S. coelicolor A3(2) P450s, CYP105N1 produced 
negligible levels of correctly folded P450 protein when expressed directly in E. coli under the control 
of the lac promoter in pET17b (Novagen). Correctly folded CYP105N1 was produced by  
co-expressing it with the molecular chaperones GroES and GroEL that have been shown to enhance 
the production of a range of active and correctly folded P450s [26]. In the presence of these proteins 
expression of active CYP105N1 was greatly enhanced with levels of P450 reaching > 900 nmol 
P450/L culture after 72 h culture. Cell fractionation revealed CYP105N1 to be a soluble protein being 
located in the cytosolic fraction following ultracentrifugation at 100,000 × g. No P450 was detected in 
the isolated E. coli membranes. After two consecutive Ni2+-affinity chromatography purification steps 
a homogeneous band was observed on sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
(SDS-PAGE) at approximately 50 kDa compared with the predicted molecular mass of the protein 
(49.2 kDa). Purified CYP105N1 had a Soret (γ) maximum at 419.2 nm and virtually equal intensities 
for the distinguishable α – (569 nm) and β – (535 nm) indicating that the P450 is in the oxidized 
enzymatically active form with the majority of the heme iron in the low spin state (Figure 2). 
Additionally, purified CYP105N1 protein has a typical P450-reduced CO spectrum, with the spectral 
maximum at 448 nm (Figure 2, inset).  
2.4. Features of the Crystal Structure of CYP105N1  
2.4.1. The Overall Structure of CYP105N1  
The crystal structure of CYP105N1 was determined by molecular replacement and was refined at a 
maximum resolution of 2.9 Å. The final model is defined in the electron density from Pro17 through 
Trp411 with two or three His412-414 (the residues of the 4 × C-terminal His tag). The overall structure 
of the CYP105N1 exhibits the typical P450-fold consisting of α-helical and β sheet domains as seen in 
all other known P450 structures (Figure 3). In detail, the tertiary structure consists of 12 major  
α-helices and three-group of β-sheets in a triangular shape. The heme cofactor is located between the 
α-helical domain and the β-sheet domain to create a substrate-binding pocket. The only conserved 
amino acid (Cys360 in CYP105N1) in all known CYP sequences serves as the fifth axial thiolate 
ligand to the heme iron. There are four CYP105N1 molecules in the asymmetric unit cell. The 
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secondary structural elements in each of the four structures are almost identical and adopt similar 
conformations with the root-mean-square deviation (RMSD) between 0.5–0.7 Å in all Cα atoms. The 
slight differences among them were found in the BC loop and FG loop regions, which are the dynamic 
structural elements in most P450s.  
Figure 2. Absolute and carbon monoxide difference spectra of CYP105N1. Absorption 
spectrum of CYP105N1 (1 μM) in the oxidized (ferric) state and (inset) the reduced carbon 
monoxide difference spectrum of CYP105N1 (1 μM) showing a Soret maximum at 450 nm. 
 
The interesting feature of the CYP105N1 structure is that a large cleft between the α-helical domain 
and the β-sheet domain exits in all four CYP105N1 structures indicating that the ligand-free 
CYP105N1 structure is in a wide-open conformation. This opening on the distal surface exposes the 
heme pocket and the long helix I to the solvent so that the substrate could easily access the active site. 
This cleft is about 20 Å wide and is formed primarily by the FG loop and helices F and G on the right 
side and by portions of the BC-loop and the B’ helix on the left side. The cleft results in the curved 
loop between the helices B and C. Also, the F and G helices swing away from the active site. Such a 
large opening in the ligand-free CYP105N1 structure might be consistent with the bulky endogenous 
substrate ceolibactin. Another structural feature of CYP105N1 is that it does not have the B' helix in 
the BC-loop region, which is present in many other CYP structures such as CYP105AB3. Instead of 
the B' helix, a coiled loop structure is present in this position in CYP105N1. 
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Figure 3. Ribbon diagram of CYP105N1. (A) The X-ray crystal structures show a typical 
cytochrome P450 fold. The ligand-free structure is represented in cyan, heme is shown as a 
red stick model; (B) Overlaid ribbon diagrams of CYP105N1 (cyan), CYP105AB3  
ligand-free (green) and CYP105A1 imidazole-bound (magenta) structures. 
 
2.4.2. The Heme-Binding Pocket 
The I-helix, the longest α-helix in P450 structures, runs across the entire molecule and above the 
heme. Several residues in the I-helix may play important roles in proton transfer during catalysis or 
providing substrate interaction. For example, the hydroxyl group of the Thr253 in the central I helix 
points toward the heme pocket. This threonine residue is highly conserved in the majority of P450s and 
may be involved in stabilizing the dioxygen complex and assist in proton transfer. The Ile245 and 
Ala249 faced to the active site may create hydrophobic environments and van der Waals interactions. 
Several other hydrophobic residues over the heme could help to form the substrate-binding pocket, 
such as Pro98, Ile100, Leu198, Ile299, and Ala400. The side chains of Arg95, Arg101, Asn188, and 
Asp398 are oriented toward the active site pocket of the enzyme as well, which may create a 
hydrogen-bonding interaction with the substrate. Thus, CYP105N1 exhibits a large cavity proximal to 
the heme and accommodates the hypothetical interaction with coelibactin.  
2.4.3. Comparison of CYP105N1 with Other CYP105s 
There are 77 family members in 32 CYP105 subfamilies identified in the CYP105 family [27]. 
Although few of CYP105 enzyme activities have been characterized [15,23–25], these results suggest 
that the CYP105 family has broad substrate specificity involved in xenobiotic oxidation as well as 
secondary metabolite biosynthesis. To date, there are five CYP105 subfamily structures in PDB: 
CYP105A1, CYP105AB3, CYP105P1, CYP105D6 and CYP105N1.  
While CYP105N1 contains about 40% amino acid sequence identity to CYP105AB3, the overall 
structures of the ligand-free forms including BC-loop and FG region are very similar (rmsd, root mean 
square deviation, 1.7 Å for all Cα atoms) (Figure 3B). Most secondary structural elements such as 
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helices I and L also superimpose quite well, however, the BC-loop, C helix and FG region show 
significant differences. There is no α helical structure in BC-loop in CYP105N1, however a B' helix is 
present in CYP105AB3. The BC-loop in CYP105N1 is slightly away from the active site compared 
with that in CYP105AB3. The N-terminus of the C helix in CYP105AB3 is bent more toward the 
solvent surface than that in CYP105N1. The F helix in both CYP105N1 and CYP105AB3 has the 
same length and the same α helical turn, however, the C-terminus of the helix G in CYP105AB3 is 
bent toward the F helix so that the FG-loop is repositioned. All these observed differences between 
CYP105N1 and CYP105AB3 may suggest the substrate specificity and recognition. 
CYP105N1 has 46% amino acid sequence identity to CYP105A1, which is known to convert 
Vitamin D3 to 25-hydroxyvitamin D3. CYP105A1 structure (PDB: 2ZBX) shows typical P450 
“closed” conformation due to imidazole binding, which increases the rmsd to 2.7 Å for all Cα  
atoms (Figure 3B). The BC loop is stretching to occupy the partial space of the cleft and the helices F 
and G rotate into the active site. Thus, both the BC loop and the FG loop are closer in order to close 
the substrate access channel. The N terminus of helix I exhibits a small bend over the heme group 
compared with the straight I helix in CYP105N1. These observed differences might indicate 
CYP105N1 would experience similar secondary structural elements movements when the enzyme 
interacts with the substrate. The ligand-free structures of CYP105P1 and CYP105D6 were compared 
with CYP105N1 structure as well. Because the His72 contacts with heme in CYP105P1, the BC-loop 
region is deep into the active site, which leads to a quite different BC-loop structure between them.  
In CYP105D6, there are some disorders in BC-loop and FG-loop, but the remaining structures were 
overlaid well with CYP105N1. This may suggest that CYP105N1 might adopt a large substrate as 
CYP105D6 does. 
2.5. Conjecture on the Enzymatic Role(s) of CYP105N1 in Production of an Active Siderophore 
The predicted structure for coelibactin as determined by the analysis of the NRPS proteins prior to 
enzymatic tailoring is given in Figure 1B. Based on analysis of known siderophore structures this 
molecule is not predicted to possess a high affinity for iron(III) [28]. Furthermore it will not satisfy the 
coordination requirements of zinc(II). Thus enzymatic modification of this structure must occur in 
order for it to bind zinc with high affinity. Hydroxylation of the aromatic nucleus or any of the three 
heterocyclic rings will not create a zinc binding site in the molecule. However reduction of the 
terminal ring of the structure in Figure 1B generates a coelibactin candidate (1, Figure 4) which will 
bind zinc under physiological conditions in a tridentate mode, utilizing the terminal imino acid and the 
nitrogen of the adjacent heterocyclic ring. Without reduction, the tridentate coordination is not 
possible. Significantly, two analogous siderophores exist, each with the terminal heterocyclic ring 
being reduced, pyochelin (2) [29] and thiazostatin (3) [30]. Whereas pyochelin chelates both iron(III) 
and zinc, coelibactin cannot bind iron(III) tightly, as the carboxylate function is too far separated from 
the phenol group. Thus, coelibactin is predicted to be selective for zinc. 
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Figure 4. Predicted structure of a possible and active coelibactin zincophore molecule. The 
predicted structure of coelibactin described by Bentley et al. [9], will not satisfy the 
coordination requirements to form a complex with zinc(II). Reduction of the terminal ring of 
the structure will generate a coelibactin candidate (1) which will bind zinc under physiological 
conditions in tridentate mode, utilizing the terminal iminoacid and the nitrogen of the adjacent 
heterocyclic ring (2). Without reduction, tridentate coordination is not possible.  
 
3. Experimental Section  
3.1. Cloning, Heterologous Expression and Purification of Streptomyces coelicolor A3(2) CYP105N1 
Genomic DNA from S. coelicolor A3(2) was isolated according to previously described procedures [9]. 
Primers 105N1F (5′-GCGCATATGAGCGCCGAATCCACCA-3′) and 105N1R  
(5′-GCGAAGCTTTCAATGGTGATGGTGGCGGCTCTCGACCCGGAA-3′) were designed to 
amplify the S. coelicolor A3(2) CYP105N1 ORF. The primers incorporate unique NdeI (underlined) 
and HindIII (double underlined) cloning sites and a C-terminal polyhistidine tag (bold) to allow 
purification of the expressed protein by affinity chromatography. PCR conditions were initial 
denaturation at 95 °C for 2 min, followed by 30 cycles of 95 °C for 20 s, 57 °C for 30 s and 68 °C for  
4 min, followed by a final extension step at 68 °C for 7 min. The integrity of CYP105N1 was 
confirmed by DNA sequencing. CYP105N1 was expressed and purified using similar conditions as 
previously described [17,18]. To improve production of correctly folded P450 protein, CYP105N1 was 
co-expressed with molecular chaperones GroES/GroEL [26]. Briefly, co-transformed cells were 
cultured overnight in Luria Bertani broth containing 100 μg/mL ampicillin and 50 μg/mL kanamycin. 
After inoculation (1:100) in 3 L of Terrific Broth containing 100 μg/mL ampicillin and 50 μg/mL 
kanamycin, growth was carried out at 37 °C and 200 rpm for 6 h. Following the addition of 1 mM  
σ-aminolevulinic acid for heme synthesis, P450 expression was induced by the addition of 1 mM 
isopropyl-β-D-thiogalactopyranoside, and chaperone expression was induced by addition of arabinose 
to a final concentration of 4 mg/mL. Cell growth was continued for an additional 72 h at 27 °C and  
170 rpm. Subsequently, the cells were harvested by centrifugation and resuspended in lysis buffer  
(250 mM sucrose, 50 mM Tris HCl, pH 7.4, 0.5 mM EDTA) and incubated with 1 mg/mL lysozyme 
for 30 min on ice prior to freezing at −80 °C. Cells were broken by freeze-thawing and the  
cytosolic fractions separated from cell debris and the membrane fraction by ultracentrifugation at  
100,000 × g for 1 h. The soluble CYP105N1 was purified by metal (Ni2+) affinity chromatography 
(Qiagen) using established methods [17,18]. 
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3.2. Crystallization, Data collection and Structure Determination of CYP105N1 
Crystals of CYP105N1 were obtained using hanging-drop vapor diffusion, in which 2 µL of a  
20 mg/mL protein solution was mixed with an equal volume of 0.1 M HEPES (pH 7.0), 0.2 M sodium 
formate, and 20% PEG 3350 at 20 °C. The plate crystals appeared within a few days. The crystals 
belong to the hexagonal space group P61 (Table 1). Full diffraction data were collected at 100 K at the 
Life Science Collaborative Access Team (LS-CAT) beamline at the Advanced Photon Source, 
Argonne National Laboratory, Argonne, IL. The X-ray data were processed and scaled with the HKL 
package programs HKL2000 [31].  
The structure of the CYP105N1 was determined by molecular replacement using the program 
PHASER [32] and the CYP105A1 structure (PDB: 2ZBX) as a search model. The initial model was 
built in COOT [33] and refinement was performed using CNS1.3 [34]. There were four molecules of 
CYP105N1 in the asymmetric unit. Final refinement statistics are given in Table 1. The coordinates 
and associated structure factors have been deposited with the Protein Data Bank (accession codes: 
3TYW). Figures were generated by Pymol [35].  
Table 1. Data Collection and Refinement Statistics. 
Data Collection Statistics Substrate-free 
Space group P61 
Unit Cell (Å) a = b = 134.537 
c = 230.58 
Molecules/asymmetric unit 4 
Data resolution (Å) 2.9 
Redundancy a 16.3 (9.9) 
Completeness% a 99.8 (99.8) 
I/σ(I) a 26.8 (6.1) 
Rmerge% a 7.1 (54.2) 
Refinement statistics  
No. of reflections used in refinement 51760 
No. of water molecules 100 
Protein atoms 12366 
Heme atoms 172 
Ligand atoms 0 
Rwork% 28.21 
Rfree% 30.05 
Rmsdb in bond lengths (Å) 0.009 
Rmsd in bond angles (º) 1.2 
Ramachandran statistics  
Favored regions (%) 94.9 
Allowed regions (%) 3.2 
Outerliers (%) 1.9 
a Values for the highest resolution shell in parentheses; b Rmsd, root mean square deviation. 
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3.3. General Methods 
Reduced carbon monoxide (CO) difference spectra for quantification of cytochrome P450 content 
were measured and calculated according to the method described by Omura and Sato [36]. Unless 
otherwise stated, all chemicals were supplied by Sigma Chemical Company (Poole, Dorset, United 
Kingdom). UV-visible absorption spectra of purified P450s were recorded using a Hitachi U-3310 
scanning spectrophotometer. 
4. Conclusions  
Herein, we present the structure of CYP105N1, the first structure of an enzyme of the coelibactin 
biosynthetic pathway to be resolved. Coelibactin is the first proposed bacterial zincophore and 
expression of the coelibactin gene cluster has been implicated in suppressing antibiotic production in  
S. coelicolor A3(2), suggesting a novel mechanism of antibiotic regulation in this organism. Zinc 
chelation has taken on significant medical importance due to the fact that in Alzheimer’s disease zinc 
has been implicated in plaque formation through increased formation of amyloid beta peptide. 
Consequently, the use of zinc chelators as therapeutic agents in Alzheimer’s disease is of growing 
interest. Coelibactin, being the first naturally occurring zincophore to be discovered, may represent a 
novel chemical scaffold for development of new therapeutic agents. Furthermore, homologues of the 
coelibactin gene cluster have been found in other streptomycetes as well as the marine actinomycete  
S. tropica, suggesting that zincophores may be a more widespread mechanism for regulating secondary 
metabolism than was previously thought and may also be screened as therapeutic agents. Efforts in our 
laboratory will continue to identify the chemical structure of the active coelibactin molecule and 
elucidate the CYP105N1 reaction details. 
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